Welcome to our dedicated page for Bowen Acquisition SEC filings (Ticker: BOWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bowen Acquisition Corp filings document its SPAC structure and public-company reporting obligations, including notices of late Form 10-K and Form 10-Q filings, material-event reports, shareholder voting matters, governance disclosures and capital-structure updates.
As a blank-check issuer, the company’s regulatory record centers on unit, warrant and rights terms, trust-account and redemption mechanics, shareholder approvals, and other disclosures tied to maintaining its capital structure and corporate status while pursuing a business combination.
Bowen Acquisition Corp is asking shareholders to approve an extension of its SPAC deadline to complete a business combination from June 14, 2026 to as late as December 31, 2026, and to approve a possible adjournment of the meeting if more time is needed.
The SPAC has a pending, already‑approved merger with Shenzhen Qianzhi BioTechnology but has not yet closed it. Public shareholders can elect to redeem their shares for cash from the trust account, estimated at about $11.55 per share based on approximately $7.78 million held in trust as of May 22, 2026, if they submit redemption requests by June 9, 2026.
If the extension is not approved and no deal is completed by June 14, 2026, Bowen would wind up, redeem all public shares from the trust and liquidate, while founder and private shares would receive no trust proceeds. Sponsors and insiders hold about 70.3% of outstanding shares and intend to vote in favor of the extension, effectively assuring its approval if all shares vote. The proxy also highlights risks including prior Nasdaq delisting, limited trading liquidity, potential Investment Company Act issues, CFIUS-related constraints because of foreign ties, and conflicts of interest for sponsors and management.
Bowen Acquisition Corp. filed a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company says additional time is needed to compile and process required information because it lacks full-time accounting and administrative staff and is pursuing an initial business combination. The notification was signed by Jiangang Luo, CEO, on May 15, 2026.
Bowen Acquisition Corp proposes an extension to move the deadline to complete its initial business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. from June 14, 2026 to as late as December 31, 2026, subject to Board discretion.
The extension would permit holders of Public Shares to elect cash redemption pro rata from the Trust Account prior to the Extraordinary General Meeting on June 11, 2026, with redemption elections due by 5:00 p.m. Eastern on June 9, 2026. If the Extension is not approved and no business combination closes by June 14, 2026, the Company will proceed to wind up, redeem Public Shares from the Trust Account and liquidate.
Bowen Acquisition Corp. notified the SEC that it is unable to file its Annual Report on Form 10-K for the period ended December 31, 2025 within the prescribed time because it lacks full-time accounting and administrative staff and is pursuing its initial business combination.
The company filed a Form 12b-25 notification signed by Jiangang Luo, Chief Executive Officer on April 1, 2026.
Bowen Acquisition Corp reported a Q3 2025 net loss of $393,970, driven by formation and operating costs and a loss on its forward purchase agreement liability, partly offset by interest income from its trust account. For the first nine months of 2025, the company recorded a net loss of $1.68 million, compared with net income of $2.43 million in the prior-year period, mainly due to the new FPA liability and financing expense.
After heavy shareholder redemptions, cash in the trust account fell to $8.22 million with only 727,871 public shares subject to redemption as of September 30, 2025, down from 6.9 million at year-end 2024. Cash outside the trust was just $17,731, and the company reported a working capital deficit of $2.42 million, leading management to state there is substantial doubt about its ability to continue as a going concern. A pending business combination with Qianzhi remains unconsummated, and Nasdaq has decided to delist the company’s securities after it failed to close the deal by an October 15, 2025 deadline.
Bowen Acquisition Corp reported that its shareholders approved a charter amendment giving the board of directors authority to extend the deadline to complete an initial business combination. The change was adopted at an extraordinary general meeting held on December 12, 2025.
A total of 2,616,701 ordinary shares were represented at the meeting. The proposal passed with 2,612,224 votes in favor and 4,477 against, with no abstentions or broker non-votes. The company stated that it is continuing to attempt to satisfy the remaining conditions to close its proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp. (BOWN) filed a Form 12b-25 (NT 10-Q) to notify a delayed filing of its Quarterly Report for the period ended September 30, 2025. The company states it cannot file within the prescribed time without unreasonable effort and expense.
Bowen cites the need for additional time to compile and process required information because it does not have full-time accounting and administrative staff. It also notes it has been in the process of seeking to consummate its initial business combination, which adds to the timing constraints.
Bowen Acquisition Corp (BOWN) calls a shareholder vote to extend its SPAC deadline. The extraordinary general meeting is set for 10:00 a.m. ET on December 12, 2025, to approve an amendment allowing up to six one‑month extensions, moving the current termination date from December 14, 2025 to as late as June 14, 2026. A separate proposal would permit adjournment if more time is needed to effect the extension.
Public shareholders may elect to redeem their shares for cash from the trust by submitting shares to the transfer agent by 5:00 p.m. ET on December 10, 2025. The company notes shareholders had already approved its business combination with Shenzhen Qianzhi BioTechnology in January 2025, but closing remains pending. If the extension fails and no deal closes by December 14, 2025, Bowen will redeem public shares and liquidate per its charter.
As of the record date November 12, 2025, 2,994,371 ordinary shares were outstanding, including 727,871 public shares. Sponsors and insiders hold 2,066,782 shares (approximately 69%) and intend to vote in favor.
Bowen Acquisition Corp. (BOWN) reported a Nasdaq delisting decision. Nasdaq notified the company on July 11, 2025 that it was not compliant with Listing Rule 5450(a)(2) requiring at least 400 total shareholders. On July 15, 2025, Nasdaq issued a delisting determination and halted trading, citing additional deficiencies, including Market Value of Listed Securities of at least $50,000,000 for 30 consecutive trading days, a minimum of 1,100,000 publicly held shares, and Market Value of Publicly Held Shares of at least $15,000,000 for 30 consecutive trading days.
After an appeal and hearing on August 21, 2025, a Panel allowed continued listing if the company completed its business combination by October 15, 2025. On October 30, 2025, Nasdaq determined to delist the securities at the open on November 3, 2025 because the combination was not completed by the deadline. Bowen has requested review by the Nasdaq Listing and Hearing Review Council; there is no assurance of continued listing or a stay.